Скачать с ютуб An overview of the CAR T-cell therapy story в хорошем качестве

An overview of the CAR T-cell therapy story

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, gives an overview of the CAR T-cell therapy story so far. The introduction of CAR T-cell therapy was a real revolution in the field of hematology. Following the breakthrough clinical results in the pivotal trials, the United States Food and Drug Administration (US FDA) and the European Medicines Agency (EMA) have approved two anti-CD19 CAR T-cell products: tisagenlecleucel for the use in children and young adults up to 25 years of age with relapsed/refractory (R/R) acute lymphoblastic leukemia, and tisagenlecleucel and axicabtagene ciloleucel for the use in adult patients with R/R diffuse large B-cell lymphoma. In addition, several clinical trials are currently investigating the use of CAR T-cells in other hematological malignancies. It is anticipated that other CAR T-cell products will soon be approved. This interview took place during the 3rd European CAR T-cell Meeting.